InVivo Therapeutics Holdings Corp. is an American research and clinical-stage biomaterials and biotechnology company focusing on treatments for spinal cord injuries.

According to the law firm press release, the Complaint alleges that the Defendants made false and misleading statements about the FDA’s approval of a clinical trial and the time for completion of the trial and submission of data to the FDA. The Complaint alleges that these misstatements and omissions by Defendants misrepresented and/or omitted material facts to the investing public, in violation of Sections 10(b) and 20(a) of the Securities Exchange Act.

According to the docket entry made on October 7, 2014, the Court entered an electronic Order appointing lead Plaintiff and lead Counsel. Lead Plaintiff filed a Complaint on October 30.

On April 3, 2015, the Court issued an Order dismissing and closing this case.